RXi, Generex See Positive Early Data from Vaccine Collaboration | GenomeWeb

RXi Pharmaceuticals said this week that it has obtained "positive early research data" in its collaboration with Generex Biotechnology subsidiary Antigene Express to use RNAi technology to develop proprietary vaccine formulations for active immunotherapy.

According to RXi, the data show that its self-delivering RNAi molecules can silence target genes up to 80 percent in hemopoietic cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.